^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    COMPANY:
    Acrivon Therap

    i
    Other names: Acrivon Therapeutics | Acrivon Therapeutics, Inc | Acrivon Therapeutics, Inc. | Acrivon Therapeutics Inc | Acrivon Therapeutics Inc. | Acrivon AB
    Related tests:
    Evidence
    News
    Evidence Level:
    Sensitive: B - Late Trials
    [No biomarker-Ovarian Cancer-ACR-368]
    Source:
    GlobeNewswire
    Test:

    OncoSignature® Test

    Title:
    Acrivon Therapeutics Announces FDA Grants Fast Track Designation for Development of ACR-368 in Platinum-Resistant Ovarian Cancer and Endometrial Cancer
    Published date:
    05/09/2023
    Excerpt:
    Acrivon Therapeutics, Inc...announced that the company has been granted two Fast Track designations by the U.S. Food and Drug Administration (FDA) for the development of ACR-368 in platinum-resistant ovarian cancer and endometrial cancer...One Fast Track development program designation was granted for the investigation of ACR-368 as a monotherapy treatment for patients with OncoSignature® positive, locally advanced, or metastatic, recurrent platinum-resistant high-grade ovarian carcinoma who have received at least one prior systemic treatment regimen.
    Evidence Level:
    Sensitive: B - Late Trials
    [No biomarker-Endometrial Cancer-ACR-368]
    Source:
    GlobeNewswire
    Test:

    OncoSignature® Test

    Title:
    Acrivon Therapeutics Announces FDA Grants Fast Track Designation for Development of ACR-368 in Platinum-Resistant Ovarian Cancer and Endometrial Cancer
    Published date:
    05/09/2023
    Excerpt:
    Acrivon Therapeutics, Inc...announced that the company has been granted two Fast Track designations by the U.S. Food and Drug Administration (FDA) for the development of ACR-368 in platinum-resistant ovarian cancer and endometrial cancer...The second Fast Track development program designation was granted for the investigation of ACR-368 as a monotherapy treatment for patients with OncoSignature positive, recurrent high-grade endometrial cancer who have received at least two prior systemic treatment regimens.